Petrelintide
   HOME

TheInfoList



OR:

Petrelintide (development name ZP8396) is an
amylin Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is co-secreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slo ...
analogue dosed once weekly, developed by
Zealand Pharma Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhag ...
for the treatment of type 2 diabetes and obesity. Preclinical data suggests it may be more effective in combination with
semaglutide Semaglutide is an anti-diabetic medication used for the treatment of type2 diabetes and an anti-obesity medication used for long-term weight management. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a ...
. In June 2024 the company announced results for a Phase 1b trial, which found 8.6 percent weight loss over 16 weeks. In March 2025, Roche entered into an exclusive collaboration and licensing agreement with
Zealand Pharma Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhag ...
to co-develop and co-commercialise petrelintide as a potential foundational therapy for overweight and obese people. This development would focus on petrelintide, both as a standalone therapy and in a fixed-dose combination with
CT-388 CT-388 is a "biased" dual GLP-1 and GIP receptor agonist/modulator with minimal to no beta-arrestin coupling at either receptor and is designed to be administered as once weekly subcutaneous injection. In a 24-week trial participants averaged 18.8 ...
for overweight and obese people.


References

{{reflist Amylin receptor agonists Experimental diabetes drugs